Corrigendum to “Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation’’ [Biochem. Pharmacol. 85(2) (2013) 257–264, (S0006295212006909), (10.1016/j.bcp.2012.10.014)];Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation

Biochemical Pharmacology

Volumn 85, Issue 2, 2013, Pages 257-264

  Collino, Massimo ^a   Benetti, Elisa ^a   Rogazzo, Mara ^a   Mastrocola, Raffaella ^a   Yaqoob, Muhammed M ^b   Aragno, Manuela ^a   Thiemermann, Christoph ^b   Fantozzi, Roberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

GW0742; High fructose corn syrup; Inflammation; Insulin resistance; PPAR

Indexed keywords

CRYOPYRIN; FRUCTOKINASE; HFCS 55; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; SWEETENING AGENT; UNCLASSIFIED DRUG; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIETARY INTAKE; DRUG EFFICACY; ENZYME ACTIVATION; HYPERLIPIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; KIDNEY INJURY; LIVER LEVEL; MALE; METABOLIC DISORDER; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84872027781     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2024.116060     Document Type: Erratum

References (51)

1. M.H. Tschop, and R.D. Dimarchi Outstanding scientific achievement award lecture 2011: defeating diabesity: the case for personalized combinatorial therapies Diabetes 61 2012 1309 1314
2. M. Collino High dietary fructose intake: sweet or bitter life World J Diabetes 2 2011 77 81
3. S.M. Moeller, S.A. Fryhofer, A.J. Osbahr 3rd, and C.B. Robinowitz The effects of high fructose syrup J Am Coll Nutr 28 2009 619 626
4. L. Tappy, and K.A. Le Metabolic effects of fructose and the worldwide increase in obesity Physiol Rev 90 2010 23 46
5. G.S. Hotamisligil Inflammation and metabolic disorders Nature 444 2006 860 867
6. B. Feve, and J.P. Bastard The role of interleukins in insulin resistance and type 2 diabetes mellitus Nat Rev Endocrinol 5 2009 305 311
7. R. Stienstra, J.A. van Diepen, C.J. Tack, M.H. Zaki, F.L. van de Veerdonk, and D. Perera Inflammasome is a central player in the induction of obesity and insulin resistance Proc Natl Acad Sci USA 108 2011 15324 15329
8. B. Vandanmagsar, Y.H. Youm, A. Ravussin, J.E. Galgani, K. Stadler, and R.L. Mynatt The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance Nat Med 17 2011 179 188
9. K. Schroder, R. Zhou, and J. Tschopp The NLRP3 inflammasome: a sensor for metabolic danger Science 327 2010 296 300
10. B. Staels, and J.C. Fruchart Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 54 2005 2460 2470
11. E. Benetti, N.S. Patel, and M. Collino The role of PPARbeta/delta in the management of metabolic syndrome and its associated cardiovascular complications Endocr Metab Immune Disord Drug Targets 11 2011 273 284
12. A. Kapoor, Y. Shintani, M. Collino, M.F. Osuchowski, D. Busch, and N.S. Patel Protective role of peroxisome proliferator-activated receptor-beta/delta in septic shock Am J Respir Crit Care Med 182 2010 1506 1515
13. M.E. Bocarsly, E.S. Powell, N.M. Avena, and B.G. Hoebel High-fructose corn syrup causes characteristics of obesity in rats: increased body weight, body fat and triglyceride levels Pharmacol Biochem Behav 97 2010 101 106
14. K.S. Collison, Z.M. Maqbool, A.L. Inglis, N.J. Makhoul, S.M. Saleh, and R.H. Bakheet Effect of dietary monosodium glutamate on HFCS-induced hepatic steatosis: expression profiles in the liver and visceral fat Obesity (Silver Spring) 18 2010 1122 1134
15. M.L. Sznaidman, C.D. Haffner, P.R. Maloney, A. Fivush, E. Chao, and D. Goreham Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity Bioorg Med Chem Lett 13 2003 1517 1521
16. Y. Takata, J. Liu, F. Yin, A.R. Collins, C.J. Lyon, and C.H. Lee PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis Proc Natl Acad Sci USA 105 2008 4277 4282
17. M. Collino, M. Aragno, S. Castiglia, G. Miglio, C. Tomasinelli, and G. Boccuzzi Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation Br J Pharmacol 160 2010 1892 1902
18. M. Collino, E. Benetti, G. Miglio, S. Castiglia, A.C. Rosa, and M. Aragno Peroxisome proliferator-activated receptor beta/delta agonism protects the kidney against ischemia/reperfusion injury in diabetic rats Free Radic Biol Med 50 2011 345 353
19. R.J. Johnson, Y.Y. Sautin, W.J. Oliver, C. Roncal, W. Mu, and L. Gabriela Sanchez-Lozada Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol B 179 2009 67 76
20. G. D'Amico, and C. Bazzi Pathophysiology of proteinuria Kidney Int 63 2003 809 825
21. V.S. Malik, B.M. Popkin, G.A. Bray, J.P. Despres, W.C. Willett, and F.B. Hu Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis Diabetes Care 33 2010 2477 2483
22. J.A. Welsh, A. Sharma, J.L. Abramson, V. Vaccarino, C. Gillespie, and M.B. Vos Caloric sweetener consumption and dyslipidemia among US adults J Am Med Assoc 303 2010 1490 1497
23. G.C. Curhan, and J.P. Forman Sugar-sweetened beverages and chronic disease Kidney Int 77 2010 569 570
24. D.A. Shoham, R. Durazo-Arvizu, H. Kramer, A. Luke, S. Vupputuri, and A. Kshirsagar Sugary soda consumption and albuminuria: results from the National Health and Nutrition Examination Survey, 1999-2004 PLoS ONE 3 2008 e3431
25. S.K. Kim, and R.F. Novak The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression Pharmacol Ther 113 2007 88 120
26. P. Cohen, and M. Goedert GSK3 inhibitors: development and therapeutic potential Nat Rev Drug Discov 3 2004 479 487
27. T. Tatarczyk, C. Ciardi, A. Niederwanger, M. Kranebitter, J.R. Patsch, and M.T. Pedrini Postprandial triglyceride-rich lipoproteins induce hepatic insulin resistance in HepG2 cells independently of their receptor-mediated cellular uptake Mol Cell Endocrinol 343 2011 71 78
28. A. Kotronen, L. Juurinen, M. Tiikkainen, S. Vehkavaara, and H. Yki-Jarvinen Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes Gastroenterology 135 2008 122 130
29. E. Barroso, R. Rodriguez-Calvo, L. Serrano-Marco, A.M. Astudillo, J. Balsinde, and X. Palomer The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation Endocrinology 152 2011 1848 1859
30. J.M. Ye, J. Tid-Ang, N. Turner, X.Y. Zeng, H.Y. Li, and G.J. Cooney PPARdelta agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle Br J Pharmacol 163 2011 556 566
31. H.T. Wu, C.T. Chen, K.C. Cheng, Y.X. Li, C.H. Yeh, and J.T. Cheng Pharmacological activation of peroxisome proliferator-activated receptor delta improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice Horm Metab Res 43 2011 631 635
32. J. Fu, S. Gaetani, F. Oveisi, J. Lo Verme, A. Serrano, and F. Rodriguez De Fonseca Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha Nature 425 2003 90 93
33. G. Miglio, A.C. Rosa, L. Rattazzi, C. Grange, M. Collino, and G. Camussi The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury Br J Pharmacol 162 2011 111 125
34. L. Vila, A. Rebollo, G.S. Adalsteisson, M. Alegret, M. Merlos, and N. Roglans Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment Toxicol Appl Pharmacol 251 2011 32 40
35. A. Korieh, and G. Crouzoulon Dietary regulation of fructose metabolism in the intestine and in the liver of the rat. Duration of the effects of a high fructose diet after the return to the standard diet Arch Int Physiol Biochim Biophys 99 1991 455 460
36. K. Nomura, and T. Yamanouchi The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease J Nutr Biochem 23 2012 203 208
37. M.A. Lanaspa, E. Tapia, V. Soto, Y. Sautin, and L.G. Sanchez-Lozada Uric acid and fructose: potential biological mechanisms Semin Nephrol 31 2011 426 432
38. M. Mazzali, J. Hughes, Y.G. Kim, J.A. Jefferson, D.H. Kang, and K.L. Gordon Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism Hypertension 38 2001 1101 1106
39. L.G. Sanchez-Lozada, E. Tapia, J. Santamaria, C. Avila-Casado, V. Soto, and T. Nepomuceno Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats Kidney Int 67 2005 237 247
40. H.J. Anders, and D.A. Muruve The inflammasomes in kidney disease J Am Soc Nephrol 22 2011 1007 1018
41. Q.H. Hu, X. Zhang, Y. Pan, Y.C. Li, and L.D. Kong Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats Biochem Pharmacol 84 2012 113 125
42. C. Jin, and R.A. Flavell Molecular mechanism of NLRP3 inflammasome activation J Clin Immunol 30 2010 628 631
43. A.V. Graca-Souza, M.A. Arruda, M.S. de Freitas, C. Barja-Fidalgo, and P.L. Oliveira Neutrophil activation by heme: implications for inflammatory processes Blood 99 2002 4160 4165
44. H. Xiao, Y. Li, J. Qi, H. Wang, and K. Liu Peroxynitrite plays a key role in glomerular lesions in diabetic rats J Nephrol 22 2009 800 808
45. T.S. Altannavch, K. Roubalova, P. Kucera, and M. Andel Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation Physiol Res 53 2004 77 82
46. C.W. Park, J.H. Kim, J.H. Lee, Y.S. Kim, H.J. Ahn, and Y.S. Shin High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent Diabetologia 43 2000 1544 1553
47. E. Letavernier, J. Perez, E. Joye, A. Bellocq, B. Fouqueray, and J.P. Haymann Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure J Am Soc Nephrol 16 2005 2395 2402
48. C.M. Larsen, M. Faulenbach, A. Vaag, A. Volund, J.A. Ehses, and B. Seifert Interleukin-1-receptor antagonist in type 2 diabetes mellitus N Engl J Med 356 2007 1517 1526
49. C.M. Larsen, M. Faulenbach, A. Vaag, J.A. Ehses, M.Y. Donath, and T. Mandrup-Poulsen Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes Diabetes Care 32 2009 1663 1668
50. A. Rissanen, C.P. Howard, J. Botha, and T. Thuren Effect of anti-IL-1beta antibody (Canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial Diabetes Obes Metab 2012 9999
51. S.L. Kempster, G. Belteki, A.J. Forhead, A.L. Fowden, R.D. Catalano, and B.Y. Lam Developmental control of the NLRP6 inflammasome and a substrate, IL-18, in mammalian intestine Am J Physiol Gastrointest Liver Physiol 300 2011 G253 G263